Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1
Zilungile Mkhize-Kwitshana
-- 1640 2023-05-04 11:18:59 |
2 format correction
Dean Liu
 -9 word(s) 1631 2023-05-05 03:27:30 |

Video Upload Options

Do you have a full video?
Send video materials Upload full video

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Damane, B.P.; Mulaudzi, T.V.; Kader, S.S.; Naidoo, P.; Savkovic, S.D.; Dlamini, Z.; Mkhize-Kwitshana, Z.L. HIV-Associated Colorectal Oncogenesis. Encyclopedia. Available online: https://encyclopedia.pub/entry/43755 (accessed on 30 June 2024).
Damane BP, Mulaudzi TV, Kader SS, Naidoo P, Savkovic SD, Dlamini Z, et al. HIV-Associated Colorectal Oncogenesis. Encyclopedia. Available at: https://encyclopedia.pub/entry/43755. Accessed June 30, 2024.
Damane, Botle Precious, Thanyani Victor Mulaudzi, Sayed Shakeel Kader, Pragalathan Naidoo, Suzana D. Savkovic, Zodwa Dlamini, Zilungile Lynette Mkhize-Kwitshana. "HIV-Associated Colorectal Oncogenesis" Encyclopedia, https://encyclopedia.pub/entry/43755 (accessed June 30, 2024).
Damane, B.P., Mulaudzi, T.V., Kader, S.S., Naidoo, P., Savkovic, S.D., Dlamini, Z., & Mkhize-Kwitshana, Z.L. (2023, May 04). HIV-Associated Colorectal Oncogenesis. In Encyclopedia. https://encyclopedia.pub/entry/43755
Damane, Botle Precious, et al. "HIV-Associated Colorectal Oncogenesis." Encyclopedia. Web. 04 May, 2023.
HIV-Associated Colorectal Oncogenesis
Edit
This entry is adapted from the peer-reviewed paper 10.3390/cancers15030748

The advancement of HIV treatment has led to increased life expectancy. People living with HIV (PLWH) are at a higher risk of developing colorectal cancers. Chronic inflammation has a key role in oncogenesis, affecting the initiation, promotion, transformation, and advancement of the disease. 

colorectal cancer inflammation metastasis EMT

1. Introduction

Colorectal cancer (CRC) is the third most common and second most deadly cancer worldwide. The disease affects more men than women, with a lifetime risk of 1 in 23 and 1 in 25, respectively. More younger adults (<50 years old) are seen, with an incidence of a 1.5% increase every year from 2014 to 2018 [1][2]. By, 2040, the estimated number of new CRC cases is projected to be around 3.2 million and thus poses a great burden and continuing global public health challenge [2]. Immunosuppression is the main factor that predisposes people living with human immunodeficiency virus (HIV) (PLWH) to infection-related cancers. A study by O’Neill et al. [3] found the incidence of CRC to be the same in HIV and non-HIV-infected individuals. The study included 27 studies performed in North America (18), Europe (7), the Pacific region (4), and South America (1) [3]. However,researchers did not include subjects from the low-middle income countries (LMIC), particularly those from the Sub-Saharan African regions. The challenge with LMIC is the disparities in socioeconomic status. Poor living conditions expose PLWH to opportunistic infections which are exacerbated by malnutrition. Poor sanitation can lead to exposure to fecal parasites including soil-transmitted helminths [4]. These parasites can cause tissue damage to the colorectum as they migrate through the body [5]. Other factors such as microbial infections and chemical agents can also cause injury, which then triggers inflammatory responses [6][7].
Prolonged exposure to inflammatory mediators such as cytokines, chemokines, and growth factors expressed during inflammatory responses result in a chronic inflammatory state associated with the initiation of CRC [8]. This has led to the use of nonsteroidal anti-inflammatory drugs (NSAIDs) for the treatment of CRCs [9]. These drugs showed an improvement and even regression in some patients, including those diagnosed with familial adenomatous polyposis (FAP), with an inherited mutation in the tumor suppressor gene, adenomatous polyposis coli (APC) [10]. Proinflammatory cytokines such as tumor necrosis factor (TNF) and interleukin (IL)-1 trigger the activation of inflammatory signaling pathways including nuclear factor kappa B (NF-ĸB), which is needed for the transcription of cytokine genes [11]. The activation of the NF-ĸB signaling pathway also promotes CRC progression [12]. Inflammatory cytokines promote the growth of tumor cells [13]. Tumor cells release cytokines that activate the NF-ĸB pathway, pushing tumor progression towards metastatic disease [14]. The activation of the NF-ĸB signaling pathway is initiated by the toll-like receptors (TLRs). The TLRs are expressed on the surface of colonic and innate immune cells. Upon activation by a pathogenic antigen(s), a cascade of signaling molecules is stimulated to elicit immunity against the pathogen and to initiate tissue repair mechanisms [15]. Both the TLRs activation and the subsequent activation of the NF-ĸB signaling pathways are associated with oncogenesis. The TLR-2, 4, and 9 have been specifically correlated with CRC [16][17][18]. TLRs are also expressed by tumor cells [19], which prompted investigations for the use of TLRs antagonists as a treatment of choice for CRC [20] and other cancers [21]. Patients with HIV were found to be at a higher risk of developing CRC [22]. Therapeutic interventions for HIV-1 using TLRs have long been suggested [23] and have been successfully shown to eliminate HIV-infected cells in pre-clinical studies [24]. This effect on inflammatory signaling pathways links CRC and HIV, which could perhaps be a strategy for “killing two birds with one stone”. This could therefore guide the efforts to develop therapeutic strategies for preventing CRC development and progression in PLWH who are on antiretroviral therapy. Herein, researchers discuss key inflammatory signaling pathways, with more focus on the TLRs- NF-ĸB/IFN and associated pathways and the possibility of targeting these pathways as a therapeutic strategy that could indiscriminately benefit HIV- and non-HIV-infected CRC patients. These therapies should take into consideration the effect of parasitic or microbial infections associated with CRC development as well.

2. HIV in Colorectal Cancer

PLWH present with CRC at a younger age than their HIV-negative counterparts. The median age at CRC diagnosis was 55 years (32–73 years), and the median period of HIV infection prior to CRC diagnosis was 15 years. An HIV-infected group had more smokers or people with a previous history of smoking than the negative group. Furthermore, high levels of tumor-infiltrating lymphocytes (TILs) and a tendency of presenting with right-sided CRC was reported [25]. HIV-infected CRC patients presented at a much younger age than those without HIV. The recurrence rate was also reported to be higher in HIV-positive (14.7%) CRC than in HIV-negative (6.8%) patients [26]. Researchers support the reports indicating that PLWH have a fourfold increased risk of developing CRC [27]. One of the mechanisms for the increased risk may be due to the Transactivator of transcription (Tat) protein, which modulates HIV-1 gene expression and facilitates the efficacy of its viral transcription. Tat is known to have oncogenic properties, and this effect was used to investigate its role in CRC oncogenesis. The main factors associated with Tat-induced CRC were its ability to significantly induce cancer cells migration, thus facilitating cancer invasiveness and metastasis. Furthermore, Tat inhibits epithelial cytodifferentiation and apoptosis, both of which are the hallmarks of cancer [27].
Conventional CRC therapy compromises immune responses and predispose patients to opportunistic infections. The use of opportunistic infection prophylaxis along with HAART was shown to decrease the risk of getting such infections [28]. Recently, HIV therapy lamivudine (3TC) was shown to attenuate CRC progression [29]. Lamivudine is a nucleoside analog and reverse transcriptase inhibitor [30]. Retrotransposon insertions [31] and repeating units [32] are associated with CRC development and progression; hence, treatment with lamivudine could halt CRC progression more profoundly in p53-mutant cell lines. The mechanism of this drug includes the induction of the interferon (IFN) response gene and the DNA damage response [29]. Xu et al. (2020) found IFNγ to play an important role in the induction of the immune checkpoint (IC) by the CRC tissue microenvironment. Apart from inducing classical ICs such as programmed cell death protein 1 (PD-1) and programmed death-ligand 1 (PD-L1), the study identified three potential novel IC-related genes induced by IFNγ. The IFNγ-inducible lysosomal thiol reductase (IFI30), guanylate binding protein1 (GBP1), and guanylate binding protein 4 (GBP4) were found to be highly expressed in CRC tumors compared to controls. The study indicated that the efficacy of IC inhibitors as cancer immunotherapy in CRC might improve by the addition of more than one IC inhibitor, with a consideration of higher instead of lower IFNγ expression levels [33].

3. Cytokine Gene Transcription Signaling in Relation to HIV-Associated CRC

Evidently, controlling HIV replication appears to play a crucial role in attenuating CRC progression [34][35]. Thus, in the efforts of finding curative HIV therapy, combination therapy with TLR agonists and broadly neutralizing antibodies (bNAbs) successfully blocked HIV-1 replication but failed to do so when used individually in people who were on anti-retroviral (ARV) therapy. Preclinical studies indicate that HIV remission could be sustained without the use of ARVs [24]. The use of HAART cannot completely eradicate HIV because of the virus’s ability to hide in the immune cells and remain dormant (HIV latency) until such time that the treatment is ceased, allowing the virus to become active and replicate. Both cytokine IL-7 and C-C chemokine ligand (CCL) 19 could increase the rate of latent HIV infection threefold. In terms of productive HIV infection, IL-7 had a fivefold increase, whilst CCL19 had a twofold increase in productive infection [36]. Latency-reversing agents (LRA) could be used to reactivate HIV transcription in dormant cells, thus stimulating the expression of surface antigens that will trigger immune responses and concurrently prevent the release of virions by HAART. However, the treatment of HIV-infected peripheral mononuclear cells (PBMCs) with TLR agonists, gene expression modulator 91 (GEM91), and a gag antisense phosphorothioate oligonucleotide showed an increased viremia caused by the induction of TLR 9 stimulation through its CpG motif. This effect was demonstrated in dose-escalation studies [37] indicating that TLR signaling contributes to challenges related to HIV treatment and possibly CRC in PLWH. Although TLRs can be beneficial in inducing immune reactivation to clear infections and prevent cancer development and progression, in certain instances, TLRs promote cancer survival and metastasis. Thus, the TLR pathway for cancer therapy is dependent on the type of TLR and the type of cell producing it. Under normal cancer immunosurveillance, TLR agonists can be beneficial to cancer cells as well. Therefore, the design of TLR-targeting agonists as well as antagonists is a promising immunotherapeutic approach to cancer [38].

TLR Signaling

Toll-like receptor family proteins are part of the innate immune system that initiates a cascade of inflammatory responses against microbial [39], parasitic [40], and viral [41] infections. There are 250 TLRs in total that have been identified thus far, with TLR 1–10 being identified in humans. The TLR family members are divided into vertebrate type (V-Type) and protostome type (P-Type). The V-Type are characterized by single-cysteine-cluster TLRs, while P-Type TLRs have several cysteine clusters. These TLRs can further be categorized into cellular (TLR 1, 2, 4, 5, 6, and 10) and intracellular membrane (TLR 3, 7, 8, and 9) TLRs (Figure 1). The TLRs are expressed on the surfaces of antigen-presenting cells (APCs) and recognize pathogen-associated molecular patterns (PAMPs) on various microorganisms. They are critical in sensing the microbiota and maintaining tolerance or triggering an immune response to pathogens. The TLRs, therefore, contribute to the prevention of gut microbial dysbiosis, associated with CRC initiation and progression [42].
Cancers 15 00748 g001 550
Figure 1. Representation of the human toll-like receptors on the cell membrane and the endosome with stimulatory pathogen-associated molecular patterns or danger-associated molecular patterns. Toll-like receptors 1 and 2 recognize triacyl lipopetides and viral proteins, whilst TLR2 and TLR6 recognize diacyl lipopeptides. The lipopolysaccharide (LPS) is recognized by TLR4 and flagellin by TLR5. TLR10 is specific for viral proteins including HIV protein receptors. The endosome TLR 3 recognizes double-stranded RNA (dsRNA). TLR 7 and 8 recognize single-stranded RNA (ssRNA) molecules, and TLR9 recognizes unmethylated CpG motifs. All endosome TLRs have the ability to recognize viral proteins.

References

  1. Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71, 209–249.
  2. Xi, Y.; Xu, P. Global colorectal cancer burden in 2020 and projections to 2040. Transl. Oncol. 2021, 14, 101174.
  3. O’Neill, T.J.; Nguemo, J.D.; Tynan, A.M.; Burchell, A.N.; Antoniou, T. Risk of Colorectal Cancer and Associated Mortality in HIV: A Systematic Review and Meta-Analysis. J. Acquir. Immune Defic. Syndr. 2017, 75, 439–447.
  4. Freeman, M.C.; Garn, J.V.; Sclar, G.D.; Boisson, S.; Medlicott, K.; Alexander, K.T.; Penakalapati, G.; Anderson, D.; Mahtani, A.G.; Grimes, J.E.T.; et al. The impact of sanitation on infectious disease and nutritional status: A systematic review and meta-analysis. Int. J. Hyg. Environ. Health 2017, 220, 928–949.
  5. Borkow, G.; Bentwich, Z. Chronic immune activation associated with chronic helminthic and human immunodeficiency virus infections: Role of hyporesponsiveness and anergy. Clin. Microbiol. Rev. 2004, 17, 1012–1030.
  6. Karin, M.; Lawrence, T.; Nizet, V. Innate Immunity Gone Awry: Linking Microbial Infections to Chronic Inflammation and Cancer. Cell 2006, 124, 823–835.
  7. Chen, L.; Deng, H.; Cui, H.; Fang, J.; Zuo, Z.; Deng, J.; Li, Y.; Wang, X.; Zhao, L. Inflammatory responses and inflammation-associated diseases in organs. Oncotarget 2018, 9, 7204–7218.
  8. Mariani, F.; Sena, P.; Roncucci, L. Inflammatory pathways in the early steps of colorectal cancer development. World J. Gastroenterol. 2014, 20, 9716–9731.
  9. Zaman, F.Y.; Orchard, S.G.; Haydon, A.; Zalcberg, J.R. Non-aspirin non-steroidal anti-inflammatory drugs in colorectal cancer: A review of clinical studies. Br. J. Cancer 2022, 127, 1735–1743.
  10. Giardiello, F.M. NSAID-induced polyp regression in familial adenomatous polyposis patients. Gastroenterol. Clin. N. Am. 1996, 25, 349–362.
  11. Lawrence, T. The nuclear factor NF-kappaB pathway in inflammation. Cold Spring Harb. Perspect. Biol. 2009, 1, a001651.
  12. Slattery, M.L.; Mullany, L.E.; Sakoda, L.; Samowitz, W.S.; Wolff, R.K.; Stevens, J.R.; Herrick, J.S. The NF-κB signalling pathway in colorectal cancer: Associations between dysregulated gene and miRNA expression. J. Cancer Res. Clin. Oncol. 2018, 144, 269–283.
  13. Kartikasari, A.E.R.; Huertas, C.S.; Mitchell, A.; Plebanski, M. Tumor-Induced Inflammatory Cytokines and the Emerging Diagnostic Devices for Cancer Detection and Prognosis. Front. Oncol. 2021, 11, 692142.
  14. Klampfer, L. Cytokines, inflammation and colon cancer. Curr. Cancer Drug Targets 2011, 11, 451–464.
  15. Duan, T.; Du, Y.; Xing, C.; Wang, H.Y.; Wang, R.F. Toll-Like Receptor Signaling and Its Role in Cell-Mediated Immunity. Front. Immunol. 2022, 13, 812774.
  16. Gao, C.; Qiao, T.; Zhang, B.; Yuan, S.; Zhuang, X.; Luo, Y. TLR9 signaling activation at different stages in colorectal cancer and NF-kappaB expression. OncoTargets Ther. 2018, 11, 5963–5971.
  17. Beilmann-Lehtonen, I.; Böckelman, C.; Mustonen, H.; Koskensalo, S.; Hagström, J.; Haglund, C. The prognostic role of tissue TLR2 and TLR4 in colorectal cancer. Virchows Arch. 2020, 477, 705–715.
  18. Luo, Q.; Zeng, L.; Tang, C.; Zhang, Z.; Chen, Y.; Zeng, C. TLR9 induces colitis-associated colorectal carcinogenesis by regulating NF-&kappa;B expression levels. Oncol. Lett. 2020, 20, 110.
  19. Du, B.; Jiang, Q.-L.; Cleveland, J.; Liu, B.-R.; Zhang, D. Targeting Toll-like receptors against cancer. J. Cancer Metastasis Treat. 2016, 2, 463–470.
  20. Messaritakis, I.; Stogiannitsi, M.; Koulouridi, A.; Sfakianaki, M.; Voutsina, A.; Sotiriou, A.; Athanasakis, E.; Xynos, E.; Mavroudis, D.; Tzardi, M.; et al. Evaluation of the detection of Toll-like receptors (TLRs) in cancer development and progression in patients with colorectal cancer. PLoS ONE 2018, 13, e0197327.
  21. Chen, X.; Zhang, Y.; Fu, Y. The critical role of Toll-like receptor-mediated signaling in cancer immunotherapy. Med. Drug Discov. 2022, 14, 100122.
  22. Nayudu, S.K.; Balar, B. Colorectal cancer screening in human immunodeficiency virus population: Are they at average risk? World J. Gastrointest. Oncol. 2012, 4, 259–264.
  23. Offersen, R.; Nissen, S.K.; Rasmussen, T.A.; Østergaard, L.; Denton, P.W.; Søgaard, O.S.; Tolstrup, M. A Novel Toll-Like Receptor 9 Agonist, MGN1703, Enhances HIV-1 Transcription and NK Cell-Mediated Inhibition of HIV-1-Infected Autologous CD4+ T Cells. J. Virol. 2016, 90, 4441–4453.
  24. Hvilsom, C.T.; Søgaard, O.S. TLR-Agonist Mediated Enhancement of Antibody-Dependent Effector Functions as Strategy For an HIV-1 Cure. Front. Immunol. 2021, 12, 704617.
  25. Sigel, C.; Cavalcanti, M.S.; Daniel, T.; Vakiani, E.; Shia, J.; Sigel, K. Clinicopathologic Features of Colorectal Carcinoma in HIV-Positive Patients. Cancer Epidemiol. Biomark. Prev. 2016, 25, 1098–1104.
  26. Pillay, S.K.; Moolla, Z.; Moodley, Y.; Madiba, T.E. Quantifying the relationship of HIV infection with clinicopathological spectrum and outcome among patients with colorectal cancer in a South African population. Afr. Health Sci. 2022, 22, 27–36.
  27. Duy, H.; Elizabeth, V.; Theo, M.; Damian, P.; Chee-Kai, C.; Robert, R. Oncogenic Properties of HIV-Tat in Colorectal Cancer Cells. Curr. HIV Res. 2007, 5, 403–409.
  28. Alfa-Wali, M.; Tait, D.; Allen-Mersh, T.; Tekkis, P.; Nelson, M.; Stebbing, J.; Antoniou, A.; Bower, M. Colorectal cancer in HIV positive individuals: The immunological effects of treatment. Eur. J. Cancer 2011, 47, 2403–2407.
  29. Rajurkar, M.; Parikh, A.R.; Solovyov, A.; You, E.; Kulkarni, A.S.; Chu, C.; Xu, K.H.; Jaicks, C.; Taylor, M.S.; Wu, C.; et al. Reverse Transcriptase Inhibition Disrupts Repeat Element Life Cycle in Colorectal Cancer. Cancer Discov. 2022, 12, 1462–1481.
  30. PubChem National Center for Biotechnology Information. PubChem Compound Summary for CID 60825, Lamivudine. 2022. Available online: https://pubchem.ncbi.nlm.nih.gov/compound/Lamivudine (accessed on 22 October 2022).
  31. Cajuso, T.; Sulo, P.; Tanskanen, T.; Katainen, R.; Taira, A.; Hänninen, U.A.; Kondelin, J.; Forsström, L.; Välimäki, N.; Aavikko, M.; et al. Retrotransposon insertions can initiate colorectal cancer and are associated with poor survival. Nat. Commun. 2019, 10, 4022.
  32. Shin, G.; Greer, S.U.; Hopmans, E.; Grimes, S.M.; Lee, H.; Zhao, L.; Miotke, L.; Suarez, C.; Almeda, A.F.; Haraldsdottir, S.; et al. Profiling diverse sequence tandem repeats in colorectal cancer reveals co-occurrence of microsatellite and chromosomal instability involving Chromosome 8. Genome Med. 2021, 13, 145.
  33. Xu, L.; Pelosof, L.; Wang, R.; McFarland, H.I.; Wu, W.W.; Phue, J.-N.; Lee, C.-T.; Shen, R.-F.; Juhl, H.; Wu, L.-H.; et al. NGS Evaluation of Colorectal Cancer Reveals Interferon Gamma Dependent Expression of Immune Checkpoint Genes and Identification of Novel IFNγ Induced Genes. Front. Immunol. 2020, 11, 224.
  34. Chaudhary, O.; Trotta, D.; Wang, K.; Wang, X.; Chu, X.; Bradley, C.; Okulicz, J.; Maves, R.C.; Kronmann, K.; Schofield, C.M.; et al. Patients with HIV-associated cancers have evidence of increased T cell dysfunction and exhaustion prior to cancer diagnosis. J. Immunother. Cancer 2022, 10, e004564.
  35. Chen, C.-H.; Chung, C.-Y.; Wang, L.-H.; Lin, C.; Lin, H.-L.; Lin, H.-C. Risk of cancer among HIV-infected patients from a population-based nested case–control study: Implications for cancer prevention. BMC Cancer 2015, 15, 133.
  36. Chavez, L.; Calvanese, V.; Verdin, E. HIV Latency Is Established Directly and Early in Both Resting and Activated Primary CD4 T Cells. PLoS Pathog. 2015, 11, e1004955.
  37. Martinsen, J.T.; Gunst, J.D.; Højen, J.F.; Tolstrup, M.; Søgaard, O.S. The Use of Toll-Like Receptor Agonists in HIV-1 Cure Strategies. Front. Immunol. 2020, 11, 1112.
  38. Javaid, N.; Choi, S. Toll-like Receptors from the Perspective of Cancer Treatment. Cancers 2020, 12, 297.
  39. Kumar, H.; Kawai, T.; Akira, S. Toll-like receptors and innate immunity. Biochem. Biophys. Res. Commun. 2009, 388, 621–625.
  40. Wojtkowiak, A. The investigations of the role of toll-like receptors (TLR) in host response to parasitic infection on the current background regarding TLR in mammals and the model nematode Caenorhabditis elegans. Wiad. Parazytol. 2007, 53, 203–211.
  41. Donninelli, G.; Gessani, S.; Del Cornò, M. Interplay between HIV-1 and Toll-like receptors in human myeloid cells: Friend or foe in HIV-1 pathogenesis? J. Leukoc. Biol. 2016, 99, 97–105.
  42. Sameer, A.S.; Nissar, S. Toll-Like Receptors (TLRs): Structure, Functions, Signaling, and Role of Their Polymorphisms in Colorectal Cancer Susceptibility. BioMed Res. Int. 2021, 2021, 1157023.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Medical Laboratory Technology
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :
Botle Precious Damane
,
Thanyani Victor Mulaudzi
,
Sayed Shakeel Kader
,
Pragalathan Naidoo
,
Suzana D. Savkovic
,
Zodwa Dlamini
,
Zilungile Lynette Mkhize-Kwitshana
View Times: 267
Revisions: 2 times (View History)
Update Date: 05 May 2023
Table of Contents
    1000/1000
    Hot Most Recent
    Video Production Service
    Feedback